Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status

2.

Silkenstedt

E

,

Dreyling

M

.

Mantle cell lymphoma—update on molecular biology, prognostication and treatment approaches

.

Hem Oncol

.

2023

;

41

(

suppl 1

):

36

-

42

.

3.

Scott

DW

,

Abrisqueta

P

,

Wright

GW

, et al.

New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies

.

J Clin Oncol

.

2017

;

35

(

15

):

1668

-

1677

.

4.

Rosenwald

A

,

Wright

G

,

Wiestner

A

, et al.

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

.

Cancer Cell

.

2003

;

3

(

2

):

185

-

197

.

5.

Freeman

CL

,

Pararajalingam

P

,

Jin

L

, et al.

Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial

.

Leukemia

.

2022

;

36

(

10

):

2479

-

2487

.

6.

Wang

ML

,

Jurczak

W

,

Jerkeman

M

, et al.

Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma

.

N Engl J Med

.

2022

;

386

(

26

):

2482

-

2494

.

7.

Ramsower

CA

,

Maguire

A

,

Robetorye

RS

, et al.

Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma

.

J Hematop

.

2020

;

13

(

4

):

231

-

238

.

8.

Cheson

BD

,

Pfistner

B

,

Juweid

ME

, et al.

Revised response criteria for malignant lymphoma

.

J Clin Oncol

.

2007

;

25

(

5

):

579

-

586

.

9.

Croci

GA

,

Hoster

E

,

Beà

S

, et al.

Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11

.

Virchows Arch

.

2020

;

477

(

2

):

259

-

267

.

10.

Dreyling

M

,

Doorduijn

J

,

Giné

E

, et al.

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

.

Lancet

.

2024

;

403

(

10441

):

2293

-

2306

.

11.

Marchetti

M

,

Visco

C

.

Cost-effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma

.

Leuk Lymph

.

2023

;

64

(

8

):

1442

-

1450

.

12.

Kumar

A

,

Soumerai

J

,

Abramson

JS

, et al.

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

.

Blood

.

2025

;

145

(

5

):

497

-

507

.

13.

Kumar

A

,

Eyre

TA

,

Lewis

KL

,

Thompson

MC

,

Cheah

CY

.

New directions for mantle cell lymphoma in 2022

.

Am Soc Clin Oncol Educ Book

.

2022

;

42

(

42

):

1

-

15

.

14.

Wang

M

,

Munoz

J

,

Goy

A

, et al.

Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study

.

J Clin Oncol

.

2023

;

41

(

3

):

555

-

567

.